Table 3.

Molecular remission rate in the PB and BM with VEN, LEN, and rituximab in R/R MCL

	3 months		6 months		9 months		12 months
	BM	PB	BM	PB	BM	PB	BM	PB
Negative	36	28	33	39	11	31	10	24
Positive	1	0	2	0	5	1	1	2
Not evaluable	22	31	24	20	43	27	48	33
Molecular remission in evaluable patients (%)	97	100	94	100	69	97	91	92
Molecular remission, intention to treat (%)	61	47	56	66	19	53	17	41